Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone for Leber hereditary optic neuropathy in China
ChiCTR-IPR-17013821Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of idebenone in Leber hereditary optic neuropathy (LHON) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Distribution of visual acuity before and after treatment and Distribution of visual acuity by mutation site before and after treatment. Started Jan 2018; status: recruiting.
02
Drugs
idebenone
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on ChiCTR-IPR-17013821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013821.